InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
59,764.76
(
0.90%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (7) Keep Next 10 Report Keyboard Shortcuts
Replies (7) Next 10 Prev Next

susmoose

Send PM Follow Ignore
Followers 6
Posts 695
Boards Moderated 0
Alias Born 02/10/2010

susmoose

Re: None

Sunday, 12/26/2010 2:10:13 PM

Sunday, December 26, 2010 2:10:13 PM

Post# of 92948
Is This True?
Don't tell me........

Bio.Org/News
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 26, 2010 1:45 EST - Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that it has suspended the Investigational New Drug (IND) Application study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).The company would not say as to why the trial is being suspeneded but did say that a more detailed press release will be sent in the near future.
Public Reply Private Reply New Post
Keep Last Read
Replies (7) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (7) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up